CHEK2 1100delC is prevalent in Swedish early onset familial breast cancer.
BACKGROUND
A truncating variant, 1100delC, in check point-kinase CHEK2, has been identified as a risk factor for familial and sporadic breast cancer. The prevalence in healthy non-breast cancer cases is low and varies between populations.


METHODS
We analyzed the prevalence of CHEK2 1100delC in 763 breast cancer patients with a defined family history and 760 controls from the Stockholm region. The breast cancer patients originated from; a population-based cohort (n = 452) and from a familial cancer clinic (n = 311), the detailed family history was known in both groups.


RESULTS
The variant was found in 2.9% of the familial cases from the population-based cohort and in 1.9% from the familial cancer clinic. In total 2.2% of the patients with a family history of breast cancer carried the variant compared to 0.7% of the controls (p = 0.03). There was no increased prevalence in sporadic patients (0.3%). The variant was most frequent in young familial patients (5.1% of cases <or=45 years, p = 0.003). The mean age at diagnosis of variant carriers was 12 years lower than in non-carriers (p = 0.001).


CONCLUSIONS
In conclusion, CHEK2 1100delC exists in the Swedish population. The prevalence is increased in familial breast cancer and the variant seems to influence age at onset.
Margolin
Sara
S
Department of Oncology, Karolinska University Hospital at Södersjukhuset, Stockholm, Sweden. sara.margolin@karolinska.se
Eiberg
Hans
H
Lindblom
Annika
A
Bisgaard
Marie Luise
ML
D000328:Adult; D017677:Age Distribution; D017668:Age of Onset; D000368:Aged; D001943:Breast Neoplasms / Q000453:epidemiology* / Q000235:genetics*; D016022:Case-Control Studies; D064447:Checkpoint Kinase 2; D015331:Cohort Studies; D005260:Female; D020022:Genetic Predisposition to Disease / Q000453:epidemiology*; D006801:Humans; D008875:Middle Aged; D009154:Mutation; D015995:Prevalence; D017346:Protein Serine-Threonine Kinases / Q000235:genetics*; D013548:Sweden / Q000453:epidemiology
D064447:Checkpoint Kinase 2; C578634:CHEK2 protein, human; D017346:Protein Serine-Threonine Kinases
Science. 1999 Dec 24;286(5449):2528-31
10617473
Cancer Epidemiol Biomarkers Prev. 1999 Oct;8(10):843-54
10548311
Br J Cancer. 2002 Jan 7;86(1):76-83
11857015
Nat Genet. 2002 May;31(1):55-9
11967536
Nat Genet. 2002 May;31(1):33-6
11984562
Am J Hum Genet. 2002 Aug;71(2):432-8
12094328
Hum Mutat. 2002 Dec;20(6):460-2
12442270
Am J Hum Genet. 2003 May;72(5):1308-14
12690581
Cancer Cell. 2003 May;3(5):421-9
12781359
BMC Med Genet. 2003 Jan 15;4:1
12529183
Genet Epidemiol. 2003 Nov;25(3):190-202
14557987
Int J Cancer. 2004 Jan 1;108(1):54-6
14618615
Cancer Res. 2003 Dec 1;63(23):8153-7
14678969
Int J Cancer. 2004 Jun 20;110(3):320-5
15095295
Am J Hum Genet. 2004 Jun;74(6):1175-82
15122511
Genet Test. 2004 Summer;8(2):127-32
15345109
Int J Cancer. 2004 Nov 10;112(3):541-3
15382084
J Med Genet. 2004 Oct;41(10):731-5
15466005
Cancer Res. 1997 Jun 15;57(12):2474-7
9192828
Eur J Hum Genet. 1998 Mar-Apr;6(2):134-9
9781057
Int J Cancer. 2005 Feb 10;113(4):575-80
15472904
Br J Cancer. 2005 Feb 28;92(4):784-90
15700044
Breast Cancer Res Treat. 2005 Mar;90(2):165-7
15803363
Eur J Cancer. 2005 Aug;41(12):1819-23
16043347
Eur J Cancer. 2005 Dec;41(18):2896-903
16239104
Scand J Urol Nephrol. 2006;40(1):23-5
16452051
BMC Cancer. 2006;6:64
16539695
PLoS Med. 2006 Jun;3(6):e168
16671833
J Clin Oncol. 2007 Jan 1;25(1):57-63
16880452
Breast Cancer Res. 1999;1(1):14-7
11250676